Technical analysis of Liquidia Corporation (LQDA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension.
Price Performance
| 1 month | +62.87% |
| 3 months | -53.23% |
| Year-to-date | +22.35% |
| 1 year | +59.73% |
| 3 years | +543.29% |
| 5 years | +921.79% |
52-Week Range
| 52-week High | $93.61 |
| 52-week Low | $22.21 |
| Avg Volume (90d) | 2.8M |
Technical Indicators
| SMA 50 | $51.89 |
| SMA 200 | $54.33 |
| Beta | 0.46 |
| 30-day Volatility (annualised) | 262.2% |
| Price vs SMA 50 | -18.7% |
| Price vs SMA 200 | -22.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $34.49 | |
| 2026-01 | $42.39 | +22.9% |
| 2026-02 | $31.02 | -26.8% |
| 2026-03 | $37.74 | +21.7% |
| 2026-04 | $39.21 | +3.9% |
| 2026-05 | $61.86 | +57.8% |
| 2026-06 | $79.73 | +28.9% |
| 2026-07 | $84.11 | +5.5% |
| 2026-08 | $68.17 | -19.0% |
| 2026-09 | $30.26 | -55.6% |
| 2026-10 | $45.06 | +48.9% |
| 2026-11 | $42.20 | -6.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-02 | $0.96 | $214M |
| 2026-08-12 | $0.70 | $168M |
| 2026-05-11 | $0.34 | $119M |
| 2026-03-05 | $0.08 | $89M |
| 2025-11-03 | $-0.45 | $81M |
| 2025-08-12 | $-0.43 | $14M |
Price
| Price | $47.38 (closing price, November 4, 2026) |
| Market Cap | $4.2B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 34.61 |
| Price / Book | 21.58 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.66 |
| Current Ratio | 2.31 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 3.78 |